HRMY Q2 2025 Earnings — Harmony Biosciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

HRMYHarmony Biosciences Holdings, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$200M+16.0% YoY

Gross Profit

$162M81.0% margin

Operating Income

$48M24.0% margin

Net Income

$40M19.8% margin

EPS (Diluted)

$0.68

QoQ Revenue Growth

+8.5%

Cash Flow

Operating Cash Flow

$79M

Free Cash Flow

$79M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$335M

Stockholders' Equity

$773M

Cash & Equivalents

$546M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$200M	$173M	+16.0%
Gross Profit	$162M	$141M	+15.4%
Operating Income	$48M	$21M	+125.6%
Net Income	$40M	$12M	+243.2%